SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

CORRESP Filing

Propanc Biopharma, Inc.
Date: Aug. 12, 2025 · CIK: 0001517681 · Accession: 0001641172-25-023078

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-282886

Date
August 13, 2025
Author
Chief
Form
CORRESP
Company
Propanc Biopharma, Inc.

Letter

RE: Propanc Biopharma, Inc.

August 12, 2025

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

F Street N.E.

Washington, D.C. 20549

Registration Statement on Form S-1, as amended

File No. 333- 282886

Concurrence in Acceleration Request

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended (the "Securities Act"), D. Boral Capital LLC, as the representative of the underwriters (the "Representative"), hereby join in the request of Propanc Biopharma, Inc. (the "Registrant"), for the acceleration of the effective date of the Registrant's Registration Statement on Form S-1 (File No. 333-282886) (as amended, the "Registration Statement"), so that the Registration Statement may be declared effective at 4:00 p.m., Eastern Time, on August 13, 2025, or as soon thereafter as practicable. The undersigned, as the Representative, confirms that it is aware of its obligations under the Securities Act.

The undersigned confirms that it has complied with and will continue to comply with, and it has been informed or will be informed by participating dealers that they have complied with or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue.

Very
truly yours,
D.
Boral capital llc

Show Raw Text
CORRESP
 1
 filename1.htm

 August
12, 2025

 VIA
EDGAR

 U.S.
Securities and Exchange Commission

 Division
of Corporation Finance

 100
F Street N.E.

 Washington,
D.C. 20549

 RE:
 Propanc Biopharma, Inc.

 Registration Statement on Form S-1, as amended

 File No. 333- 282886

 Concurrence
in Acceleration Request

 Ladies
and Gentlemen:

 Pursuant
to Rule 461 promulgated under the Securities Act of 1933, as amended (the "Securities Act"), D. Boral Capital LLC, as the
representative of the underwriters (the "Representative"), hereby join in the request of Propanc Biopharma, Inc. (the "Registrant"),
for the acceleration of the effective date of the Registrant's Registration Statement on Form S-1 (File No. 333-282886) (as amended,
the "Registration Statement"), so that the Registration Statement may be declared effective at 4:00 p.m., Eastern Time, on
August 13, 2025, or as soon thereafter as practicable. The undersigned, as the Representative, confirms that it is aware of its obligations
under the Securities Act.

 The
undersigned confirms that it has complied with and will continue to comply with, and it has been informed or will be informed by participating
dealers that they have complied with or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended,
in connection with the above-referenced issue.

 Very
 truly yours,

 D.
 Boral capital llc

 By:
 /s/
 Philip Wiederlight

 Name:
 Philip
 Wiederlight

 Title:
 Chief
 Operating Officer